▲ +33.72% Upside Potential
This price target is based on 10 analysts offering 12 month price targets for BioLife Solutions in the last 3 months. The average price target is $46.67, with a high forecast of $61.00 and a low forecast of $17.00. The average price target represents a 33.72% upside from the last price of $34.90.
The current consensus among 10 contributing investment analysts is to buy stock in BioLife Solutions. This Buy consensus rating has held steady for over two years.
BioLife Solutions, Inc. develops, manufactures, and supplies bioproduction tools for the cell and gene therapy industry in North America, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; and the ThawSTAR line that includes automated vial and cryobag thawing products that control the heat and timing of the thawing process of biologic materials. The company also provides evo shipping containers that are cloud-connected passive storage and transport containers for temperature-sensitive biologics and pharmaceuticals; and liquid nitrogen laboratory freezers, cryogenic equipment, and accessories. The company markets and sells its products directly, as well as through third party distributors. BioLife Solutions, Inc. was founded in 1987 and is headquartered in Bothell, Washington.